135 related articles for article (PubMed ID: 17120198)
1. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
Blum KA; Johnson JL; Niedzwiecki D; Piro LD; Saven A; Peterson BA; Byrd JC; Cheson BD;
Cancer; 2006 Dec; 107(12):2817-25. PubMed ID: 17120198
[TBL] [Abstract][Full Text] [Related]
2. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
[TBL] [Abstract][Full Text] [Related]
3. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ohmachi K; Ando K; Ogura M; Uchida T; Itoh K; Kubota N; Ishizawa K; Yamamoto J; Watanabe T; Uike N; Choi I; Terui Y; Usuki K; Nagai H; Uoshima N; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2059-64. PubMed ID: 20626754
[TBL] [Abstract][Full Text] [Related]
5. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.
Oki Y; McLaughlin P; Pro B; Hagemeister FB; Bleyer A; Loyer E; Younes A
Cancer; 2005 Aug; 104(4):781-7. PubMed ID: 15973667
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
Friedberg JW; Cohen P; Chen L; Robinson KS; Forero-Torres A; La Casce AS; Fayad LE; Bessudo A; Camacho ES; Williams ME; van der Jagt RH; Oliver JW; Cheson BD
J Clin Oncol; 2008 Jan; 26(2):204-10. PubMed ID: 18182663
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.
Tobinai K; Ishizawa K; Ogura M; Itoh K; Morishima Y; Ando K; Taniwaki M; Watanabe T; Yamamoto J; Uchida T; Nakata M; Terauchi T; Nawano S; Matsusako M; Hayashi M; Hotta T
Cancer Sci; 2009 Oct; 100(10):1951-6. PubMed ID: 19594547
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.
Zinzani PL; Tani M; Marchi E; Stefoni V; Alinari L; Musuraca G; Gabriele A; Pileri S; Baccarani M
Haematologica; 2004 Mar; 89(3):309-13. PubMed ID: 15020269
[TBL] [Abstract][Full Text] [Related]
10. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
Bouwhuis SA; el-Azhary RA; McEvoy MT; Gibson LE; Habermann TM; Witzig TE; Pittelkow MR
Int J Dermatol; 2002 Jun; 41(6):352-6. PubMed ID: 12100691
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
12. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
Kalinka-Warzocha E; Wajs J; Lech-Maranda E; Ceglarek B; Holowiecki J; Federowicz I; Walewski J; Czyz J; Robak T; Warzocha K;
Cancer; 2008 Jul; 113(2):367-75. PubMed ID: 18470902
[TBL] [Abstract][Full Text] [Related]
14. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab.
Tobinai K; Watanabe T; Tanimoto K; Maruyama D; Nakata M; Itoh K; Morishima Y; Ogura M; Usui N; Kasai M; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y
Cancer Sci; 2009 Jul; 100(7):1344-50. PubMed ID: 19432900
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
[TBL] [Abstract][Full Text] [Related]
18. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
Krykowski E; Warzocha K; Robak T
Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):317-21. PubMed ID: 8744653
[TBL] [Abstract][Full Text] [Related]
19. Primary localized stages I and II non-Hodgkin's lymphoma of the nasopharynx: a retrospective 17-year single institutional experience.
Mohammadianpanah M; Ahmadloo N; Mozaffari MA; Mosleh-Shirazi MA; Omidvari S; Mosalaei A
Ann Hematol; 2009 May; 88(5):441-7. PubMed ID: 18931844
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
